Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 17/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 12/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1123613 | 0.88 | PTGS2 (0.60) | KIF11PTGS2CYP2C9PDPK1PTGS1 | |
| SCHEMBL1123783 | 0.88 | PTGS2 (0.61) | KIF11PTGS2CYP2C9PDPK1PTGS1 | |
| SCHEMBL7216291 | 0.86 | PTGS2 (0.62) | KIF11PTGS2CYP2C9PDPK1PTGS1 | |
| SCHEMBL1270876 | 0.86 | PTGS2 (0.62) | KIF11PTGS2CYP2C9PDPK1PTGS1 | |
| SCHEMBL1123587 | 0.77 | PTGS2 (0.53) | PTGS2CYP2C9PDPK1PTGS1CA12 | |
| SCHEMBL1123619 | 0.77 | PTGES (0.65) | PTGS2CYP2C9PDPK1PTGS1CA12 | |
| SCHEMBL1123796 | 0.74 | PTGS2 (0.46) | KIF11PTGS2CYP2C9PDPK1PTGS1 | |
| SCHEMBL2465743 | 0.72 | PTGS2 (0.55) | PTGS2CYP2C9PDPK1PTGS1CA12 | |
| SCHEMBL6732634 | 0.72 | PTGS1 (0.61) | KIF11PTGS2PTGS1CA12CA1 | |
| SCHEMBL6732217 | 0.71 | KIF11 (0.58) | KIF11PTGS2CYP2C9PDPK1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196915-A1 | Antitumor 1,2-Diphenylpyrrole Compounds and their Preparation Process | ARGON PHARMA, S.L. (ES) | 2012-08-02 | — | — | US | claimed |
| EP-2459532-A1 | ANTITUMOR 1,2-DIPHENYLPYRROLE COMPOUNDS AND THEIR PREPARATION PROCESS | Argon Pharma S.L. (ES) | 2012-06-06 | — | — | EP | claimed |
| EP-2284154-A1 | Antitumor 1,2-diphenylpyrrole compounds and their preparation process | Argon Pharma S.L. (ES) | 2011-02-16 | — | — | EP | claimed |
| WO-2011012660-A1 | ANTITUMOR 1,2-DIPHENYLPYRROLE COMPOUNDS AND THEIR PREPARATION PROCESS | ARGON PHARMA, S. L. (ES) | 2011-02-03 | — | — | WO | claimed |
| US-20120196915-A1 | Antitumor 1,2-Diphenylpyrrole Compounds and their Preparation Process | ARGON PHARMA, S.L. (ES) | 2012-08-02 | — | — | US | disclosed |
| EP-2459532-A1 | ANTITUMOR 1,2-DIPHENYLPYRROLE COMPOUNDS AND THEIR PREPARATION PROCESS | Argon Pharma S.L. (ES) | 2012-06-06 | — | — | EP | disclosed |
| EP-2284154-A1 | Antitumor 1,2-diphenylpyrrole compounds and their preparation process | Argon Pharma S.L. (ES) | 2011-02-16 | — | — | EP | disclosed |
| WO-2011012660-A1 | ANTITUMOR 1,2-DIPHENYLPYRROLE COMPOUNDS AND THEIR PREPARATION PROCESS | ARGON PHARMA, S. L. (ES) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196915-A1 | Antitumor 1,2-Diphenylpyrrole Compounds and their Preparation Process | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TPD52L2, CYC1 | KIF11 3158/4885PTGS2 1289/4885CYP2C9 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.